In conclusion, the additional value of renal artery stenting needs to be established in patients who are aggressively medically managed; and a functional test to help us discern patients who would benefit from renal revascularization from patients who would not is needed. Because the issue of benefit from renal artery revascularization is still undecided, patients should be encouraged to enroll in randomized clinical trials. Only when we have solid evidence that patients will benefit significantly from renal artery revascularization in addition to optimal medical therapy should we incorporate RAS revascularization into routine medical practice.
Friday, November 13, 2009
Atherosclerotic renal artery stenosis
This review covers the ins and outs of medical treatment including secondary prevention of atherosclerotic events and the safety of ACEIs. Concerning stenting: